Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Katy Warner / Wikimedia Commons

Steven Collis, longtime chief executive officer of drug distributor AmerisourceBergen, made more than $32 million in his company's 2016 fiscal year, per a federal filing released Friday. That total includes the actual realized gains from Collis' stock options, not the estimated fair value, as well as his salary and bonuses.

For Collis, his payday was actually lower than the year before, when he took home more than $34 million.

Why it matters: Business was good for AmerisourceBergen, which delivers drugs to pharmacies, hospitals, clinics and other health care sites and may be the largest company you've never heard of. The company netted a $1.4 billion profit on $147 billion of revenue last year. That means AmerisourceBergen is twice as big as companies like Procter & Gamble or Target.

Similar to pharmacy benefit managers, drug distributors thrive on higher drug prices, which has stoked public outrage and may invite federal regulation. They also don't get nearly the same scrutiny as the drug companies that list the prices.

AmerisourceBergen was upfront with investors in November about what will happen if drug prices get targeted. "If the frequency or rate of branded and generic pharmaceutical price increases slows, our results of operations could be adversely affected," the company said in its annual 10-K filing.

Go deeper

Ina Fried, author of Login
34 mins ago - Technology

Scoop: Google is investigating the actions of another top AI ethicist

Google CEO Sundar Pichai. Photo by Mateusz Wlodarczyk/NurPhoto via Getty Images

Google is investigating recent actions by Margaret Mitchell, who helps lead the company's ethical AI team, Axios has confirmed.

Why it matters: The probe follows the forced exit of Timnit Gebru, a prominent researcher also on the AI ethics team at Google whose ouster ignited a firestorm among Google employees.

2 hours ago - Politics & Policy

Scoop: Joe Biden's COVID-19 bubble

Photo illustration: Aïda Amer/Axios. Photo: Joe Raedle/Getty Images

The incoming administration is planning extraordinary steps to protect its most prized commodity, Joe Biden, including requiring daily employee COVID tests and N95 masks at all times, according to new guidance sent to some incoming employees Tuesday.

Why it matters: The president-elect is 78 years old and therefore a high risk for the virus and its worst effects, despite having received the vaccine. While President Trump's team was nonchalant about COVID protocols — leading to several super-spreader episodes — the new rules will apply to all White House aides in "high proximity to principals."

Justice Department drops insider trading inquiry against Sen. Richard Burr

Sen. Richard Burr (R-N.C.) walking through the Senate Subway in the U.S. Capitol in December 2020. Photo: Stefani Reynolds/Getty Images

The Department of Justice told Sen. Richard Burr (R-N.C.) on Tuesday that it will not move forward with insider trading charges against him.

Why it matters: The decision, first reported by the New York Times, effectively ends the DOJ's investigation into the senator's stock sell-off that occurred after multiple lawmakers were briefed about the coronavirus' potential economic toll. Burr subsequently stepped down as chair of the Senate Intelligence Committee.